Modeling a lethal prostate cancer variant with small-cell carcinoma features

Clinical Cancer Research

Volumn 18, Issue 3, 2012, Pages 666-677

  Tzelepi, Vassiliki ^a,c   Zhang, Jiexin ^b   Lu, Jing Fang ^a   Kleb, Brittany ^a   Wu, Guanglin ^a   Wan, Xinhai ^a   Hoang, Anh ^a   Efstathiou, Eleni ^a   Sircar, Kanishka ^b   Navone, Nora M ^a   Troncoso, Patricia ^b   Liang, Shoudan ^b   Logothetis, Christopher J ^a   Maity, Sankar N ^a   Aparicio, Ana M ^a  

^a David H Koch Center for Applied Research of Genitourinary Cancers   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN D1;

ADULT; AGED; ANIMAL MODEL; ANIMAL TISSUE; AR GENE; ARTICLE; CASTRATION; CCND1 GENE; CELL STRUCTURE; COMPARATIVE GENOMIC HYBRIDIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; COPY NUMBER VARIATION; CPG ISLAND; DISEASE MODEL; DNA METHYLATION; GENE; GENE AMPLIFICATION; GENE CONTROL; GENE DELETION; GENE EXPRESSION PROFILING; GENE LOCUS; GENOME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; MALE; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; RB1 GENE; RETINOBLASTOMA; SMALL CELL CARCINOMA; TUMOR XENOGRAFT; UBE2C GENE; UPREGULATION;

AGED; ANIMALS; CARCINOMA, SMALL CELL; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84863013857     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1867     Document Type: Article

References (48)

1. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-80. (Pubitemid 34791096)
2. Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE, et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 2007;110:1729-37. (Pubitemid 47557297)
3. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:65-71.
4. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, et al. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 2011;71:846-56.
5. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 2001;12 Suppl 2: S135-40.
6. Wynn SS, Nagabundi S, Koo J, Chin NW. Recurrent prostate carcinoma presenting as omental large cell carcinoma with neuroendocrine differentiation and resulting in bowel obstruction. Arch Pathol Lab Med 2000;124:1074-6. (Pubitemid 30602052)
7. Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006;30:684-93. (Pubitemid 44264993)
8. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010;120:4478-92.
9. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009;138:245-56.
10. Aparicio A, Harzstark AL, Lin E, Corn PG, Araujo JC, Tu S, et al. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol 2011;29: abstr 4666.
11. Pounds S, Morris SW. Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics 2003;19: 1236-42. (Pubitemid 36850216)
12. van Oijen MG, Medema RH, Slootweg PJ, Rijksen G. Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol 1998;110:24-31. (Pubitemid 28294731)
13. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009;220:292-6.
14. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, et al. SMAD4- dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470:269-73.
15. Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res 2009;15: 5338-49.
16. Beasley MB, Lantuejoul S, Abbondanzo S, Chu WS, Hasleton PS, Travis WD, et al. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 2003;34:136-42. (Pubitemid 36258804)
17. Igarashi T, Jiang SX, Kameya T, Asamura H, Sato Y, Nagai K, et al. Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Mod Pathol 2004;17:1259-67. (Pubitemid 39312952)
18. van Ree JH, Jeganathan KB, Malureanu L, van Deursen JM. Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol 2010;188:83-100.
19. Sage J, Straight AF. RB's original CIN? Genes Dev 2010;24:1329-33.
20. Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, et al.DNAcopy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 2007;67:692-700. (Pubitemid 46709438)
21. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
22. Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, et al. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 2004;23:6621-9. (Pubitemid 39265525)
23. Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, et al. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 2000;60:3623-30. (Pubitemid 30482185)
24. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 1993;8:1063-7. (Pubitemid 23087441)
25. Liu H, Wang J, Epner EM. Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences. Blood 2004;104:2505-13. (Pubitemid 39331854)
26. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999;39:135-48.
27. Schron DS, Gipson T, Mendelsohn G. The histogenesis of small cell carcinoma of the prostate. An immunohistochemical study. Cancer 1984;53:2478-80. (Pubitemid 14102490)
28. Helpap B, Kollermann J. Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 1999;434:385-91. (Pubitemid 29261526)
29. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 2009;69:603-9.
30. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 2011;42:11-7.
31. Nath S, Banerjee T, Sen D, Das T, Roychoudhury S. Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10. J Biol Chem 2011;286:15666-77.
32. Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, et al. Phospho- MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J 2011;30:2405-19.
33. Beltran H, Rickman D, Park K, Sboner A, Macdonald T, Tagawa ST, et al. Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets. J Clin Oncol 2011;29 suppl 7: abstr 19.
34. Janssen A, Medema RH. Mitosis as an anti-cancer target. Oncogene 2011;30:2799-809.
35. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, et al. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate 2011; 71:1668-79.
36. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, et al. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991;46:31-6.
37. Chatterjee SJ, George B, Goebell PJ, Alavi-Tafreshi M, Shi SR, Fung YK, et al. Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol 2004; 203:762-70. (Pubitemid 38961562)
38. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090-4. (Pubitemid 28183188)
39. Wikenheiser-Brokamp KA. Retinoblastoma regulatory pathway in lung cancer. Curr Mol Med 2006;6:783-93.
40. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-66.
41. Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 2008;121:3853-7.
42. Comstock CE, Augello MA, Schiewer MJ, Karch J, Burd CJ, Ertel A, et al.Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. J Biol Chem 2011;286:8117-27.
43. Lehn S, Tobin NP, Berglund P, Nilsson K, Sims AH, Jirstrom K, et al. Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. Am J Pathol 2010;177:2886-97.
44. Watanabe G, Albanese C, Lee RJ, Reutens A, Vairo G, Henglein B, et al. Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol Cell Biol 1998;18:3212-22. (Pubitemid 28240494)
45. Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010;29:3593-604.
46. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A 2008;105:12182-7.
47. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009;16:37-44.
48. Culine S, El Demery M, Lamy PJ, Iborra F, Avances C, Pinguet F. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178:844-8. (Pubitemid 47224949)